Six Ophthalmology Faculty and Trainees Receive Research to Prevent Blindness Awards
Jia Yin, MD, PhD, MPH, Receives RPB Physician-Scientist Award
Dr. Ayellet Segrè, PhD, Receives RPB/Glaucoma Foundation Career Advancement Award
The majority of these variants lie in noncoding regions and likely affect glaucoma through dysregulation of gene expression in specific ocular cell types. Dr. Segrè, a statistical geneticist, will use a combination of single cell genomics, transcriptomics, and epigenomics to identify genetic regulatory effects in the aqueous humor outflow pathways, retina, and optic nerve head at cellular resolution. These results will be integrated with genetic associations with POAG to identify novel disease-causing genes and pathogenic cell types, and propose new neuroprotective drug targets for glaucoma.
Ryoji Amamoto, PhD, Receives RPB Career Development Award
Isdin Oke, MD, Receives RPB Career Development Award
Lyvia J. Zhang Receives AOCOO-HNF Medical Student Eye Research Fellowship
Zhang will complete a one-year research fellowship focused on the Boston keratoprosthesis (KPro) artificial cornea device under the mentorship of faculty member Thomas Dohlman, MD. She will study the retention rate and complications associated with the device, and develop a model to optimize post-operative management.
Madhura Shah Receives Janssen Medical Student Eye Research Fellowship
Shah previously spent a year in the laboratory of Bruce Ksander, PhD, analyzing outcomes in a non-human primate model of induced optic neuropathy treated with a novel “epigenetic reprogramming” gene therapy to restore visual function. She will continue to build on that research with her RPB grant, under the mentorship of both Dr. Ksander and Joe Rizzo, MD. Applying the expertise of the Ksander laboratory, Shah aims to epigenetically reprogram induced-pluripotent stem cells (iPSCs) obtained from Dr. Rizzo’s optic neuropathy patient population. This personalized research promises to determine if the results using cells derived from individual patients could be used to assess the potential response to therapy. It applies state-of-the-art technology and will provide important data for a future human clinical trial.